MorphoSys AG / MorphoSys Nominates Karin Eastham and Marc Cluzel as

New Supervisory Board Members . Processed and transmitted by Thomson

Reuters ONE. The issuer is solely responsible for the content of this


MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced

today that the Company will nominate Ms. Karin Eastham and Dr. Marc

Cluzel as new members of the Supervisory Board at the Company's Annual

Shareholder Meeting on Thursday, May 31, 2012. Ms. Eastham and Dr.

Cluzel will replace Prof. Dr. Jurgen Drews and Dr. Metin Colpan. Prof.

Drews has been a member of MorphoSys AG's Supervisory Board since

1998, while Dr. Colpan joined in 2004.

"We are delighted to be able to present two highly qualified

candidates for MorphoSys's Supervisory Board," commented Dr. Gerald

Moller, Chairman of the Supervisory Board of MorphoSys AG. "Karin

Eastham and Marc Cluzel both have outstanding track records in our

industry and have contributed to the successful performance of several

companies over the course of their careers."

Karin Eastham is an experienced financial executive who currently

serves as director on the Corporate Boards of Illumina, Inc., Amylin,

Inc., Trius Therapeutics, Inc. and Geron Corporation. From May 2004 to

September 2008, she served as Executive Vice President and Chief

Operating Officer and as a member of the Board of Trustees of the

Burnham Institute for Medical Research, a non-profit corporation

engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham

served as Senior Vice President, Finance, Chief Financial Officer and

Secretary of Diversa Corporation. She previously held similar

positions with CombiChem, Inc. and Cytel Corporation. She also held

several positions, including Vice President, Finance, at Boehringer

Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S.

and a M.B.A. from Indiana University and is a Certified Public


Dr. Marc Cluzel, an established innovator and leader in the

pharmaceutical industry, has more than 20 years of extensive knowledge

and experience in Research & Development and product registration in

the USA, Europe and Japan. Dr. Cluzel founded C&F consulting in 2011

and serves also as Executive Vice President of Product Development at

HUYA Bioscience International, LLC. Dr. Cluzel served as global head

of R&D for Sanofi from 2007 to 2011, as Executive Vice President of

Research & Development for Sanofi (Formerly Sanofi-Aventis SA) and

before 2009 as its Senior Vice President of Science and Medical

Affairs. He was also since 2002 chairman and CEO of Sanofi-Synthelabo

R&D France then Sanofi-Aventis R&D France. His career began in

hospital medical care and gradually transitioned to research at Johns

Hopkins University, Baltimore and Guy's Hospital, London. Dr. Cluzel

holds both an MD and a PhD from the University of Montpellier, France.

The full agenda for the Annual General Meeting is available on the

Company's website under

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library

technology in the pharmaceutical industry. By successfully applying

this and other patented technologies, MorphoSys has become a leader in

the field of therapeutic antibodies, one of the fastest-growing drug

classes in human healthcare. The company's AbD Serotec unit uses HuCAL

and other antibody technologies to generate superior monoclonal

antibodies for research and diagnostic applications.

Together with its pharmaceutical partners, MorphoSys has built a

therapeutic pipeline of more than 70 human antibody drug candidates

for the treatment of cancer, rheumatoid arthritis, and Alzheimer's

disease, to name just a few. With its ongoing commitment to new

antibody technology and drug development, MorphoSys is focused on

making the healthcare products of tomorrow. MorphoSys is listed on the

Frankfurt Stock Exchange under the symbol MOR. For regular updates

about MorphoSys, visit

HuCAL@, HuCAL GOLD@, HuCAL PLATINUM@, CysDisplay@, RapMAT@ and arYla@

are registered trademarks of MorphoSys. Ylanthia@ and 100 billion high

potentials are trademarks of MorphoSys AG.

Slonomics@ is a registered trademark of Sloning BioTechnology GmbH, a

subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements

concerning the MorphoSys group of companies. The forward-looking

statements contained herein represent the judgment of MorphoSys as of

the date of this release and involve risks and uncertainties. Should

actual conditions differ from the Company's assumptions, actual

results and actions may differ from those anticipated. MorphoSys does

not intend to update any of these forward-looking statements as far as

the wording of the relevant press release is concerned.

Media Release:

This announcement is distributed by Thomson Reuters on behalf of

Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other

applicable laws; and

(ii) they are solely responsible for the content, accuracy and

originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE